|
|
Post by winner on Dec 1, 2020 11:18:42 GMT -5
Thanks cjm18. Greatly appreciated.......
|
|
|
|
Post by matt on Dec 1, 2020 12:55:44 GMT -5
It appears this should end speculation that a December dilution might occur. Not saying it won't just that the odds have now moved it off the radar. Disagreements with an explanation are certainly welcome. I think some additional dilution is inevitable, but I agree that this happening in December is not so likely. There is still a huge disconnect between what a prudent company would hold in balance sheet cash and what MNKD has available so tapping the financial markets for additional equity while the stock price is a high is not a bad idea. However, with the recent developments the timing for the next raise has become a lot more flexible. |
|
|
|
Post by cedafuntennis on Dec 1, 2020 17:19:03 GMT -5
Correct, but timing is now at our choosing. Like when the previous incompetent management had the opportunity to raise cash at cca. $20/share and never thought about it. Now we can wait till $10 or so, then raise some capital to grow on.
|
|
|
|
Post by sportsrancho on Dec 1, 2020 17:31:09 GMT -5
We’re going to need money way before we get to $10 a share, what are you people smoking🤣 We do not have enough money to carry us till we get royalties.
|
|
|
|
Post by letitride on Dec 1, 2020 17:42:31 GMT -5
We’re going to need money way before we get to $10 a share, what are you people smoking🤣 We do not have enough money to carry us till we get royalties. The Good Stuff. Lets Go! |
|
|
|
Post by tingtongtung on Dec 1, 2020 17:46:51 GMT -5
We’re going to need money way before we get to $10 a share, what are you people smoking🤣 We do not have enough money to carry us till we get royalties. Like when they did reverse split, they should have done 1:10 and raised more money (like many here were saying).. But, they did 1:5 and barely got any money, and the stock price just came back, almost negating the whole thing. Well, I'm not the CEO.. JMO :-) |
|
|
|
Post by cretin11 on Dec 1, 2020 18:54:48 GMT -5
We’re going to need money way before we get to $10 a share, what are you people smoking🤣 We do not have enough money to carry us till we get royalties. Cmon sports, we have it on good authority (from an esteemed poster on this board) that we’ll see $10 a share within a month or two, surely we can hold out until then!!! 🤪 |
|
|
|
Post by uvula on Dec 1, 2020 19:24:13 GMT -5
I have it on good authority (someone here said it this morning) that the new BOD director is a philanthropist so she was probably brought in to donate money to mnkd.
|
|
|
|
Post by sportsrancho on Dec 1, 2020 19:55:43 GMT -5
I was just thinking I am on 14 different StockTwits threads.. and none of them are like the ST Mannkind thread, on the Mannkind thread people literally make things up ..good and bad. I think they’re pumping the stock so they can jump out whenever they hit break even, when in reality they should just diversify a little bit at that time... then relax and let it ride.
|
|
|
|
Post by cretin11 on Dec 1, 2020 20:53:19 GMT -5
I was just thinking I am on 14 different StockTwits threads.. and none of them are like the ST Mannkind thread, on the Mannkind thread people literally make things up ..good and bad. I think they’re pumping the stock so they can jump out whenever they hit break even, when in reality they should just diversify a little bit at that time... then relax and let it ride. Exactly. Best thing I ever did was diversify part of my MNKD position into ZM, TTD, SHOP and TSLA a year or so ago. Much more relaxed now! There have always been MNKD blatant pumpers, there’s been a cultish aspect to it, somewhat understandable given the genuine brilliance of Al. |
|
|
|
Post by mytakeonit on Dec 2, 2020 2:21:42 GMT -5
MNKd pps is irrevelant to what is going to happen. With the partnership with UTHR and future developments about to happen ... pps will eventually follow. Have you all noticed that volume is starting to climb? There is interest in MNKD. It's simple to me ...
But, that's mytakeonit
|
|
|
|
Post by lakon on Dec 4, 2020 8:09:01 GMT -5
Last FDA approval (Afrezza) drove PPS over $10 under a completely different (crazy) capital structure.
FDA approval of TreT could drive PPS over $10. Under the old capital structure, that's only worth about $2. It would be reasonable to expect additional exuberance and short covering. At $50/sh, we breech similar exuberance to the last approval, but do not account for any potential short squeeze. Of course, accounting for dilution would reduce the price somewhat; however, the prospects of Afrezza and TreT plus more on the way, including the implications of a true proof-of-concept of multiple Technosphere approvals from the FDA on the market. Well, even I, would not care to speculate on that outcome...
Let's just agree to disagree that $25-30/sh is somewhat reasonable exuberance for the current market up to and through initial approval. I would not be surprised to see prices peak much higher for a very short time. If so, and if possible, I will dump my shares and possibly go short to ride up and back down before reestablishing a long position.
|
|
|
|
Post by dh4mizzou on Dec 4, 2020 8:12:20 GMT -5
Last FDA approval (Afrezza) drove PPS over $10 under a completely different (crazy) capital structure. FDA approval of TreT could drive PPS over $10. Under the old capital structure, that's only worth about $2. It would be reasonable to expect additional exuberance and short covering. At $50/sh, we breech similar exuberance to the last approval, but do not account for any potential short squeeze. Of course, accounting for dilution would reduce the price somewhat; however, the prospects of Afrezza and TreT plus more on the way, including the implications of a true proof-of-concept of multiple Technosphere approvals from the FDA on the market. Well, even I, would not care to speculate on that outcome... Let's just agree to disagree that $25-30/sh is somewhat reasonable exuberance for the current market up to and through initial approval. I would not be surprised to see prices peak much higher for a very short time. If so, and if possible, I will dump my shares and possibly go short to ride up and back down before reestablishing a long position. It just moved ;-) |
|
|
|
Post by peppy on Dec 4, 2020 8:28:24 GMT -5
Last FDA approval (Afrezza) drove PPS over $10 under a completely different (crazy) capital structure. FDA approval of TreT could drive PPS over $10. Under the old capital structure, that's only worth about $2. It would be reasonable to expect additional exuberance and short covering. At $50/sh, we breech similar exuberance to the last approval, but do not account for any potential short squeeze. Of course, accounting for dilution would reduce the price somewhat; however, the prospects of Afrezza and TreT plus more on the way, including the implications of a true proof-of-concept of multiple Technosphere approvals from the FDA on the market. Well, even I, would not care to speculate on that outcome... Let's just agree to disagree that $25-30/sh is somewhat reasonable exuberance for the current market up to and through initial approval. I would not be surprised to see prices peak much higher for a very short time. If so, and if possible, I will dump my shares and possibly go short to ride up and back down before reestablishing a long position. SOLD! |
|
|
|
Post by morfu on Dec 4, 2020 8:51:32 GMT -5
Last FDA approval (Afrezza) drove PPS over $10 under a completely different (crazy) capital structure. FDA approval of TreT could drive PPS over $10. Under the old capital structure, that's only worth about $2. It would be reasonable to expect additional exuberance and short covering. At $50/sh, we breech similar exuberance to the last approval, but do not account for any potential short squeeze. Of course, accounting for dilution would reduce the price somewhat; however, the prospects of Afrezza and TreT plus more on the way, including the implications of a true proof-of-concept of multiple Technosphere approvals from the FDA on the market. Well, even I, would not care to speculate on that outcome... Let's just agree to disagree that $25-30/sh is somewhat reasonable exuberance for the current market up to and through initial approval. I would not be surprised to see prices peak much higher for a very short time. If so, and if possible, I will dump my shares and possibly go short to ride up and back down before reestablishing a long position. Two weeks ago I posted this (in the "Share price movement" thread commenting a similar post from a different poster): """ >> It's significantly undervalued
This question and various answers keeps popping up.. what price tag can you put on hopes?
So far there is no certainty that any of the various pathways will earn the shareholder significant money.
You can argue the likelihood based on Trep T status or adult American Afrezza sales, but there is no guarantee, only hopes.
How do you price them in?
Some say 3$, you say 8$ here..
Can someone give me a fair share price estimate based on the assumption that we will earn 5ct per share in 2023, 10ct in 2024 and 5ct more each year that follows?
How do you do math that out? Assuming something like 40ct per share 10years from now and P/E of 100 gives us 40$ as share price then, shall we just guess 10% of that as a fair value and
say 4$ goal right now? """
Your answer to my question seems to be look at that previous event, when Afrezza was approved.. We had significant dilutions over the last years, a second FDA approval is less significant than the first and I have the feeling that short and other players were way more active back then! So, while I doubt that we will see a raise to 25$/share upon TreT approval (which was also not declined before unlike Afrezza, so the "surprise" is smaller), this is an interesting idea!
|
|
